Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Colon Cancer. 8 results shown below.

Capecitabine and Celecoxib With or Without Radiation Therapy in Treating Patients With Colorectal Cancer Previously Treated With Fluorouracil

[Complete title: A Phase II Trial of Maintenance ADAPT Therapy with Capecitabine and Celecoxib in Patients with Metastatic Colorectal Cancer]
Principal Investigator: Edward Lin, MD
Study Number: 7707
Phase: II

A Phase I study of the Raf kinase and receptor tyrosine kinase inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in children with refractory solid tumors or refractory leukemias
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0413
Phase: I

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP P-5
Phase: III

A Study in Second Line Metastatic Colorectal Cancer

[Complete title: A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine]
Principal Investigator: Veena Shankaran
Study Number: 20101327
Phase: III

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

[Complete title: Gilead GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111441
Phase: II

Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors (MDX1105-01)

[Complete title: A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors (WIRB's Study#: 1107927, Protocol#: 20082100)]
Principal Investigator: Scott Tykodi, MD
Study Number: 7104
Phase: I

Previous Study | Return to List | Next Study Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

[Complete title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy]
Principal Investigator: William Harris
Study Number: 7627
Phase: III

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.